Ocular Therapeutix (OCUL) reported a Q1 net loss Monday of $0.38 per diluted share, narrower than a loss of $0.49 a year earlier.
Analysts polled by FactSet expected a loss of $0.38.
Revenue for the quarter ended March 31 was $10.7 million, compared with $14.8 million a year earlier.
Analysts surveyed by FactSet expected $17 million.
The company's shares were down 8.4% in recent Monday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。